New York City, New York Jul 29, 2022 (Issuewire.com) - In the research on oncolytic virus (OV) research, OV-mediated mono-therapeutic efficacy remains controversial, especially for metastatic or advanced patients who require systemically deliverable therapies. In today’s landscape, many researchers are working on OV combination therapies, which have shown potential to improve the therapeutic efficacy of OV-mediated therapy and prevent tumor recurrence.
Supported by dedicated scientists and cutting-edge platforms, Creative Biolabs now updates the streamlined service on oncolytic virotherapy development for combination therapy with cancer immunotherapy, covering adoptive T cell therapy (ACT), immune checkpoint inhibitor (ICI), cytokines, cancer vaccines, and chemoradiotherapy, to help scientists worldwide to reduce costs and increase efficiency.
- OV Combination Therapy with ACT
Creative Biolabs has long been devoted to the development and application of oncolytic virotherapy for combination therapy. Based on advanced technologies and years of experience in cancer therapy study, the one-stop OV and ACT combination therapy development services now cover tumor-infiltrating lymphocyte therapy (TIL), chimeric antigen receptor T-cell therapy (CAR-T), T-cell receptor-engineered T-cells therapy (TCR-T), and dendritic cell and cytokine-induced killer cell immunotherapy (DC-CIK). Multiple types of animal models which have severe immune system function defects are also available for xenograft transplantation studies.
- OV Combination Therapy with Immune Checkpoint Inhibitors (ICIs)
The expert team at Creative Biolabs has long-term devoted to the development and application of ICIs and oncolytic virotherapy and has developed specific oncolytic viruses to combine with different types of ICIs to improve the effectiveness of cancer treatment. The service portfolio contains assay development and arming OV with ICI payloads. Various cell lines and animal models are provided to advance research in vitro and in vivo.
- OV Combination Therapy with Cytokines
The team is also sophisticated to introduce cytokines in oncolytic viral vectors, aiming to reduce adverse events, revert resistance, and enhance treatment responsiveness. The most essential cytokines are included, such as colony-stimulating factors (CSFs), interferons (IFNs), interleukin (IL), tumor necrosis factor (TNF), and chemokines (e.g. CCL2, CCL5, CXCL9, and CXCL10).
“We have built up a systemic R&D mode in oncotherapy with an innovative OncoVirapy™ platform to support the research on combination therapy. This platform can guide custom projects from oncolytic virus engineering, construction, in vitro assays, and in vivo assays for proof-of-concept study, all the way to oncolytic virus manufacture. Our expert scientists and dedicated team members are here to make sure you get the backing and services you need to be most successful in your research endeavors as you drive to the discovery that will shape the future.” said Bella Smith, the Business Development Executive at Creative Biolabs.
Detailed information about the platforms and services can be found at https://www.creative-biolabs.com/oncolytic-virus.
About Creative Biolabs
Empowered by leading technology and years of experience in biomedical science, Creative Biolabs is dedicated to offering comprehensive, end-to-end oncolytic virus therapy development services. The whole pipeline covers oncolytic virus engineering, the Vitro validation study, in vivo preclinical study, disease-specific oncolytic virotherapy development, etc.
Media Contact
Candy Swift marketing@creative-biolabs.com https://www.creative-biolabs.com/oncolytic-virus
